



ASX ANNOUNCEMENT

17 September 2024

Opyl Enters Strategic Partnership with Alithia Life Sciences

Melbourne, Australia – Opyl Limited (ASX: OPL) an emerging leader in AI-powered clinical trial design, is pleased to announce a non-exclusive strategic partnership with **Alithia Life Sciences**, a well-recognised CRO specialising in advanced clinical research solutions.

Key Highlights:

- A non-exclusive partnership with Alithia Life Sciences to enhance clinical trial projects using TrialKey's AI-driven analytics.
- Opyl Limited will receive \$5,000+ AUD per report as part of the partnership.
- TrialKey's reports provide valuable insights, including probability of success predictions, optimised trial designs, and data validation to support clinical trial planning.
- Both companies will work together on marketing activities to highlight the advantages of AI-driven solutions in clinical trials.

About the Partnership:

This strategic collaboration enables Alithia to utilise TrialKey's advanced AI-driven simulation and predictive analytics within their clinical trial projects. The comprehensive reports from TrialKey offer detailed insights into trial variables, competitor assessments, patient recruitment strategies, and site selection recommendations.

Alithia will incorporate these reports to enhance the quality and efficiency of their trial projects, aligning with their commitment to data-backed approaches in clinical research. This partnership reflects the shared goal of driving effective trial outcomes through data-driven insights.

To further promote the benefits of AI-driven trial design and data validation, both Opyl and Alithia will actively engage in joint marketing efforts within the clinical trial industry.

**Additional Information:**

Confidentiality: Both parties acknowledge the confidential nature of information shared during this partnership and commit to maintaining its confidentiality, using it solely for the purpose of the collaboration.

Termination: The partnership can be terminated by either party with 30 days' written notice.

Marketing and Publicity: Opyl and Alithia reserve the right to issue press releases, create case studies (subject to mutual approval), and use each other's name and logo in marketing materials related to this collaboration.

This strategic partnership marks a significant step in leveraging AI to optimise clinical trial designs and improve overall outcomes.

Please Note: The specific terms and conditions of the partnership are governed by the Mutual Non-Disclosure Agreement between the two companies.

Tina Soulis, Founder and Director at Alithia Life Sciences, commented:

"We are excited to collaborate with Opyl and leverage TrialKey's advanced AI-driven trial design capabilities. This partnership aligns with our commitment to delivering high-quality, data-backed clinical trial projects to our clients. By incorporating TrialKey's insights into our projects, we are confident in our ability to deliver more efficient and effective clinical trials."

Opyl Limited Executive Chair, Saurabh Jain, added:

"This partnership with Alithia is another step in our journey to support the global clinical trial community with AI-enhanced trial designs. By providing our reports to Alithia, we ensure mutual success and demonstrate the value of our data-driven approach."

About Alithia Life Sciences

Alithia Life Sciences is a leading CRO based in Melbourne, Australia, offering comprehensive clinical research services to biopharmaceutical companies. With a strong commitment to quality and innovation, Alithia supports its clients in navigating the complex clinical trial landscape.



This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.